80 Compañías | 333 productos médicos
The Rapid COVID-19 Antigen Test is an in vitro immunochromatographic assay for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct nasopharyngeal (NP) swab from individuals who are suspected of COVID-19 by their healthcare provider. It is intended to aid in the rapid diagnosis of SARS-CoV-2 infections.
The SARS-CoV-2 ELITe MGB Kit is intended to determine, quantitatively and qualitatively, the presence of SARS-CoV-2 Virus RNA, responsible for the well known pathology COVID-19. In complete compliance with WHO guidelines, the kit targets two genes of SARS-CoV-2: RdRp and ORF8. The kit is CE-IVD marked, it allows the possibility of carrying out 240 Tests or 96, on the ELITe InGenius platform, the sample-to-result solution, capable of analysing up to 12 samples simultaneously and of reanalyzing them without the need for further extraction of genetic material.
The Randox SARS-CoV-2 IgG (RBD & NP) array utilizes patented biochip technology to simultaneously detect IgG antibodies against both leading COVID-19 diagnostic antigens; Spike Receptor Binding Domain (RBD) and Nucleocapsid protein (NP). Maximum sensitivity is ensured through detection of antibodies against both proteins making the assay superior compared to other commercially available serology tests where false negative results are common. Measurement of both RBD and NP IgG antibodies also provides an opportunity to discriminate vaccinated versus naturally infected individuals based on leading vaccine candidates.